This study explores if a medicine called nerandomilast can help people with lung fibrosis, a lung condition, linked to certain rheumatic diseases, which are diseases where the immune system attacks the body. If standard treatments, like immunosuppressants (medicines that lower the immune system's activity), haven't improved lung function, you may qualify for this study. Participants are randomly placed into two groups: one group takes nerandomilast tablets, and the other takes placebo tablets, which look the same but have no active medicine. Everyone continues their usual treatment for their rheumatic disease.
The study lasts about 7.5 to 13 months, with 9 to 10 visits to the study site. During these visits, doctors check lung function, perform chest imaging, and ask participants to fill out questionnaires about their symptoms and quality of life. They compare the groups to see if the medicine works and monitor any side effects.
- Study duration is up to 13 months with 9 to 10 visits.
- Participants continue their current rheumatic disease treatment.
- Regular checks on health and possible side effects are done.